Intermediate Grade Lung Neuroendocrine Neoplasm clinical trials at UCSF
1 research study open to eligible people
open to eligible people ages 18 years and up
This phase III trial studies cabozantinib to see how well it works compared with placebo in treating patients with neuroendocrine or carcinoid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Cabozantinib is a chemotherapy drug known as a tyrosine kinase inhibitor, and it targets specific tyrosine kinase receptors, that when blocked, may slow tumor growth.
San Francisco, California and other locations
Our lead scientists for Intermediate Grade Lung Neuroendocrine Neoplasm research studies include Emily K. Bergsland.